Rosetta Genomics Ltd is primarily active in the biotechnology industry.

The main competitors of Rosetta Genomics Ltd in the market include companies like Veracyte, Inc., Guardant Health, Inc., and Exact Sciences Corporation.

Rosetta Genomics Ltd, founded in 2000, is a leading molecular diagnostics company specializing in developing and commercializing innovative diagnostic tests. Headquartered in Israel, the company focuses on personalized medicine and offers a range of diagnostic products for the detection of various diseases. With a strong emphasis on microRNA technology, Rosetta Genomics has developed proprietary algorithms and bioinformatics tools that facilitate accurate diagnostic testing. The company has received numerous approvals and certifications for its products, enabling healthcare professionals to make informed treatment decisions. Rosetta Genomics Ltd is dedicated to advancing precision medicine through its cutting-edge technologies and commitment to improving patient outcomes.

Rosetta Genomics Ltd, a leading genomics company, has achieved several significant milestones. This include obtaining regulatory approval for their groundbreaking diagnostic tests, securing strategic partnerships with reputable pharmaceutical companies, and achieving key milestones in the development of personalized medicine. Furthermore, the company has successfully commercialized innovative genomic products, expanding its market reach globally. Rosetta Genomics Ltd's dedication to advancing genomics research and personalized medicine has positioned it as a prominent player in the industry. With its dynamic accomplishments, Rosetta Genomics Ltd continues to revolutionize the field of genomics and improve patient outcomes.

Rosetta Genomics Ltd primarily operates in the United States and Israel.

Rosetta Genomics Ltd represents a commitment to precision medicine and cutting-edge genomic solutions. With an emphasis on personalized diagnosis and treatment, the company aims to revolutionize healthcare by leveraging its advanced microRNA-based technologies. Rosetta Genomics embraces a patient-centric approach, delivering accurate and actionable information to facilitate better treatment decisions. Continually pushing boundaries in the field of molecular diagnostics, the company strives to improve patient outcomes and enhance therapeutic options. Through innovation, expertise, and a dedication to improving lives, Rosetta Genomics remains at the forefront of molecular profiling, empowering healthcare professionals with valuable insights for effective disease management.

9 analysts currently rate the Rosetta Genomics stock: 8 recommend buying, 1 holding and 0 selling.

Rosetta Genomics Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Rosetta Genomics share trades at 0,00 EUR (0,00 USD).

Rosetta Genomics Ltd is a company specializing in oncology, whose business model is based on the development and marketing of diagnostic tests, therapies, and tools for cancer research. The company is divided into three main business areas: molecular diagnostics, personalized medicine, and research. All three areas are closely interconnected and contribute to the development of innovative products. Molecular diagnostics involves the development of diagnostic tests specifically targeting cancer types such as lung, breast, stomach, colon, liver, pancreatic, and thyroid cancer. Rosetta Genomics utilizes state-of-the-art technologies like Next-Generation Sequencing and qPCR to develop these tests. Personalized medicine aims to personalize and improve the treatment of cancer patients. Rosetta Genomics offers high-throughput personalized therapies and diagnostic tests based on the analysis of biomarkers such as miRNA, mRNA, and gene expression profiles. These tests enable physicians to plan more precise and effective treatments. The company's research division develops its own products and technologies for cancer research. Rosetta Genomics offers research tools that enable the identification of new biomarkers, the development of prognostic tests, and the exploration of new therapeutic approaches. Rosetta Genomics has a wide range of products on the market, including the miRview® test, which allows for rapid and reliable diagnosis of lung, colon, and pancreatic cancer. The on-site miRview® Mets test enables precise determination of the origin of metastasized tumors. Key products also include the MSK-CC Panel and the IBD-CC Panel, both widely used in the research community for their quick results and high accuracy. In summary, Rosetta Genomics' business model is focused on the development and marketing of innovative diagnostic tests, personalized medicines, and technologies for cancer research. Through the use of cutting-edge technologies, the company is able to offer sophisticated products aimed at more precise diagnosis and treatment of cancer.

Liikevaihtoa ei voida laskea Rosetta Genomics:lle tällä hetkellä.

Voittoa ei voida laskea Rosetta Genomics:lle tällä hetkellä.

P/E-suhdetta ei voida laskea Rosetta Genomics:lle tällä hetkellä.

P/S-suhdetta ei voida laskea Rosetta Genomics:lle tällä hetkellä.

Rosetta Genomics:n Eulpool-laatuscore on 4/10.

Rosetta Genomics:n ISIN on IL0011026494. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Rosetta Genomics:n WKN on A0MMDG. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Rosetta Genomics:n ticker on ROSGQ. Tämä pörssinoteeraus käytetään Rosetta Genomics-osakkeiden kauppaan pörssissä.

Rosetta Genomics maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Rosetta Genomics kuuluu sektoriin 'Terveydenhuolto'.

Rosetta Genomics:n osingot jaetaan valuutassa USD.